Bio-Techne Corporation has reported its financial results for the fiscal year ending June 30, 2025. The company achieved a 5% increase in consolidated net sales, reaching $1.2 billion compared to fiscal 2024. This growth was primarily attributed to strong commercial execution in the Protein Sciences segment, with organic growth also at 5%. However, consolidated net earnings experienced a significant decrease of 56% from the previous year. This decline was influenced by a non-recurring loss on an arbitration award, asset impairment of those held-for-sale, and restructuring-related charges. Non-GAAP adjusted consolidated net earnings before taxes were reported at $98.5 million, a decrease from $185.7 million in fiscal 2024. The company identified several adjustments impacting earnings, including costs recognized upon the sale of acquired inventory and amortization of intangibles. Bio-Techne develops and sells life science reagents, instruments, and services worldwide, playing a key role in scientific investigations and clinical diagnostics.